Back to top

Analyst Blog

Dr. Reddy's Laboratories Ltd. (RDY - Analyst Report) recently announced the launch of its therapeutic equivalent generic version of GlaxoSmithKline plc's (GSK - Analyst Report) Lamictal XR (lamotrigine) extended-release tablets (25 mg, 50 mg, 100 mg, 200 mg, 300 mg) in the US.

The launch followed the approval by the US Food and Drug Administration (FDA) of Abbreviated New Drug Application (ANDA) submitted by the company for Lamictal XR.

Lamictal XR is used in combination with other therapies for treating primary generalized tonic-clonic seizures and partial onset seizures in patients with a minimum age of 13 years.According to IMS Health, Lamictal XR (branded and generic version both) generated US revenues of approximately $300.5 million MAT (moving annual total) for the last 12 months ending Apr 2013.

Dr. Reddy's boasts of a strong generic product portfolio. Revenues at the Global Generics segment were up 17.5% to $1.5 billion for the fiscal year 2013 (ended Mar 31).

Strong sales in North America and emerging markets were primarily responsible for the growth displayed by the Global Generics division. Generics revenue increased in North America (up 19%), Russia (up 27%), other CIS (Commonwealth of Independent States) markets (up 28%), India (up 13%) and the rest of the world/RoW (up 42%). 

In Jan 2013, Wockhardt Ltd., an Indian company, launched the generic version of Lamictal XR in the US in 25mg, 50mg, 100mg, 200mg and 300mg extended release tablets.

Dr. Reddy's carries a Zacks Rank #3 (Hold) while GlaxoSmithKline carries a Zacks Rank #4 (Sell).  Currently, companies like Santarus, Inc. and Salix Pharmaceuticals Ltd. (SLXP - Analyst Report) look more attractive in the pharma space with a Zacks Rank #1 (Strong Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
ERBA DIAGNO… ERB 3.00 +3.09%
SANCHEZ ENE… SN 34.18 +2.67%
THE PANTRY… PTRY 21.02 +2.09%
INTEL CP INTC 35.15 +1.88%
PIPER JAFFR… PJC 54.54 +1.70%